Rosetta Genomics Gets NY State Permit for microRNA Tests | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics has received a clinical laboratory permit from the New York State Department of Health allowing the firm to offer its microRNA-based tests to physicians and patients in the state.

The firm currently sells three tests — the miRview meso, miRview mets, and miRview squamous — that are run at its own Philadelphia-based CAP-accredited, CLIA-certified lab.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.